- Home
- RDIB vs LXEO Comparison
RDIB vs LXEO Comparison
Compare RDIB & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDIB | LXEO |
|---|---|---|
| Founded | 1937 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.6M | 348.7M |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RDIB | LXEO |
|---|---|---|
| Price | $16.40 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 308.5K | ★ 638.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $654,000.00 |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $3.99 |
| 52 Week High | $24.00 | $10.99 |
Technical Indicators
Market Signals| Indicator | RDIB | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 35.97 |
| Support Level | $9.95 | $4.01 |
| Resistance Level | $17.40 | $5.38 |
| Average True Range (ATR) | 3.73 | 0.22 |
| MACD | 0.21 | -0.08 |
| Stochastic Oscillator | 36.14 | 14.81 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.